Validations Queue
111,300 candidate doc → node links pending adjudication. Each was auto-generated by cosine similarity ≥ 0.55 between document and prediction embeddings (bge-base-en-v1.5, 768-dim). Showing page 30 of 88, 50 rows by similarity. Adjudicating updates doc_node_links.reviewed=true with the chosen polarity, writes per-link rows to audit_log, and removes the row from this queue. Phase 4 inference will use confirmed corroborates/contradicts links as Bayesian evidence.
Pending (total)
111,300
Reviewed
13
Filtered
4,390
page 30 / 88
Showing on page
50
Filters
URL params control source + min-similarity threshold
Bulk auto-confirm by similarity threshold
Confirm or label (corroborates / contradicts) all unreviewed links above a similarity threshold in one transaction. Each affected row writes a per-link audit_log entry. Capped at 1,000 links per call. Use Preview first.
Source0 selected · 0 visible
Bulk action
| Sim | Doc | Source | Pred | Domain | Prior | |
|---|---|---|---|---|---|---|
| 0.60 | FDA ANDA215759: LENALIDOMIDE (LENALIDOMIDE) — BIOCON PHARMA | fda 2026-04-27 | IND_012 NVIDIA BioNeMo platform + Evo 2 model fundamentally compresses a century of biology into a decade — Evo 2 achieves 90% accuracy in BRCA1 predictions; AI models will seamlessly transition generated biological designs into practical, synthesized clinical... Jensen Huang | Biotech/Longevity | 68% | |
| 0.60 | FDA ANDA211523: DAPAGLIFLOZIN (DAPAGLIFLOZIN) — AIZANT | fda 2026-04-06 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.60 | FDA NDA219249: ITOVEBI (INAVOLISIB) — GENENTECH INC | fda 2026-04-15 | AI_031 AGI will be defined by its ability to autonomously formulate novel scientific hypotheses — effectively solving '100 years of biology' in a fraction of the historical time required, via continuous hypothesis-generation and experimental iteration. Demis Hassabis | Biotech/Longevity | 51% | |
| 0.60 | FDA NDA214275: UPTRAVI (SELEXIPAG) — ACTELION | fda 2026-05-23 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.60 | FDA ANDA211015: VERAPAMIL HYDROCHLORIDE (VERAPAMIL HYDROCHLORIDE) — SOMERSET THERAPS LLC | fda 2026-05-20 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.60 | FDA ANDA214733: VENETOCLAX (VENETOCLAX) — DR REDDYS | fda 2026-05-15 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.60 | FDA ANDA210329: TADALAFIL (TADALAFIL) — JUBILANT GENERICS | fda 2026-05-15 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.60 | FDA ANDA217027: DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE (AMPHETAMINE ASPARTATE) — GRANULES | fda 2026-05-20 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.60 | FDA ANDA208052: LURASIDONE HYDROCHLORIDE (LURASIDONE HYDROCHLORIDE) — ZYDUS PHARMS | fda 2026-05-14 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.60 | FDA NDA209805: STEGLUJAN (ERTUGLIFLOZIN) — MSD SUB MERCK | fda 2026-06-03 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.60 | FDA NDA208400: XATMEP (METHOTREXATE SODIUM) — AZURITY | fda 2026-05-27 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.60 | FDA NDA209637: OZEMPIC (SEMAGLUTIDE) — NOVO | fda 2026-06-01 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.60 | FDA BLA761063: EMGALITY (GALCANEZUMAB-GNLM) — ELI LILLY AND CO | fda 2026-06-05 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.60 | FDA ANDA217298: TOFACITINIB CITRATE (TOFACITINIB CITRATE) — MSN | fda 2026-06-03 | COD_BIO_002 An AI-designed Isomorphic or peer drug enters or completes Phase 1 by end 2027 Codex Research Pack | Biotech/Longevity | 50% | |
| 0.60 | FDA BLA761458: EXDENSUR (DEPEMOKIMAB-ULAA) — GLAXOSMITHKLINE LLC | fda 2026-06-10 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.60 | FDA BLA761458: EXDENSUR (DEPEMOKIMAB-ULAA) — GLAXOSMITHKLINE LLC | fda 2026-06-10 | IND_010 Autonomous orbital manufacturing (facilitated by companies like Varda Space Industries) will successfully return pharmaceutical products processed in microgravity that are commercially superior to those manufactured on Earth by 2026 — new Biotech front... Jared Isaacman | Biotech/Longevity | 43% | |
| 0.60 | FDA NDA016673: DEXTROSE 5% IN PLASTIC CONTAINER (DEXTROSE) — BAXTER HLTHCARE | fda 2026-06-11 | 245_009 Breaking plastic-degradation technology could become a supplement that breaks microplastics in the gut before absorption Peter Diamandis | Biotech/Longevity | 45% | |
| 0.60 | FDA NDA016673: DEXTROSE 5% IN PLASTIC CONTAINER (DEXTROSE) — BAXTER HLTHCARE | fda 2026-06-11 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.60 | FDA ANDA040517: METHADONE HYDROCHLORIDE (METHADONE HYDROCHLORIDE) — SPECGX LLC | fda 2026-06-18 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.60 | FDA NDA020232: FIORICET W/ CODEINE (ACETAMINOPHEN) — ACTAVIS LABS UT INC | fda 2026-06-18 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.60 | FDA ANDA207171: HYDROCODONE BITARTRATE AND ACETAMINOPHEN (ACETAMINOPHEN) — LANNETT CO INC | fda 2026-06-18 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.60 | FDA ANDA209037: HYDROCODONE BITARTRATE AND ACETAMINOPHEN (ACETAMINOPHEN) — ABHAI LLC | fda 2026-06-18 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.60 | FDA ANDA210758: OXYCODONE HYDROCHLORIDE (OXYCODONE HYDROCHLORIDE) — SPECGX LLC | fda 2026-06-18 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.60 | FDA ANDA207808: HYDROCODONE BITARTRATE AND ACETAMINOPHEN (ACETAMINOPHEN) — RHODES PHARMS | fda 2026-06-18 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.60 | FDA ANDA077154: FENTANYL-75 (FENTANYL) — SPECGX LLC | fda 2026-06-18 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.60 | FDA ANDA040241: METHADONE HYDROCHLORIDE (METHADONE HYDROCHLORIDE) — VISTAPHARM LLC | fda 2026-06-18 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.60 | FDA ANDA089828: ACETAMINOPHEN AND CODEINE PHOSPHATE (ACETAMINOPHEN) — STRIDES PHARMA INTL | fda 2026-06-18 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.60 | FDA ANDA202662: OXYCODONE HYDROCHLORIDE (OXYCODONE HYDROCHLORIDE) — EPIC PHARMA LLC | fda 2026-06-18 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.60 | FDA ANDA214507: HALOPERIDOL DECANOATE (HALOPERIDOL DECANOATE) — MEITHEAL | fda 2026-06-25 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.60 | FDA ANDA076914: TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN (ACETAMINOPHEN) — GRAVITI PHARMS | fda 2026-06-18 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.60 | FDA ANDA211487: HYDROCODONE BITARTRATE AND ACETAMINOPHEN (ACETAMINOPHEN) — ASCENT PHARMS INC | fda 2026-06-18 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.60 | FDA ANDA217596: LACOSAMIDE (LACOSAMIDE) — PROD DEVELOPMENT | fda 2026-06-15 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.60 | FDA NDA220436: NAVITRUX (FOSAPREPITANT) — AVYXA HOLDINGS | fda 2026-06-24 | IND_010 Autonomous orbital manufacturing (facilitated by companies like Varda Space Industries) will successfully return pharmaceutical products processed in microgravity that are commercially superior to those manufactured on Earth by 2026 — new Biotech front... Jared Isaacman | Biotech/Longevity | 43% | |
| 0.60 | FDA NDA200534: OXYCODONE HYDROCHLORIDE (OXYCODONE HYDROCHLORIDE) — GENUS LIFESCIENCES | fda 2026-06-18 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.60 | FDA ANDA201448: OXYCODONE AND ACETAMINOPHEN (ACETAMINOPHEN) — SANKALP LIFECARE | fda 2026-06-18 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.60 | FDA ANDA212418: ACETAMINOPHEN AND CODEINE PHOSPHATE (ACETAMINOPHEN) — ELITE LABS INC | fda 2026-06-18 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.60 | FDA ANDA217329: FOSTAMATINIB DISODIUM (FOSTAMATINIB DISODIUM) — ANNORA PHARMA | fda 2026-06-17 | COD_BIO_002 An AI-designed Isomorphic or peer drug enters or completes Phase 1 by end 2027 Codex Research Pack | Biotech/Longevity | 50% | |
| 0.60 | FDA ANDA205105: METHYLPHENIDATE HYDROCHLORIDE (METHYLPHENIDATE HYDROCHLORIDE) — IMPAX LABS INC | fda 2026-04-21 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.60 | FDA ANDA220147: TOLVAPTAN (TOLVAPTAN) — ALKEM LABS LTD | fda 2026-04-21 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.60 | FDA ANDA207110: BOSENTAN (BOSENTAN) — WATSON LABS INC | fda 2026-04-14 | COD_BIO_002 An AI-designed Isomorphic or peer drug enters or completes Phase 1 by end 2027 Codex Research Pack | Biotech/Longevity | 50% | |
| 0.60 | FDA BLA761298: PAVBLU (AFLIBERCEPT-AYYH) — AMGEN INC | fda 2026-04-28 | COD_BIO_002 An AI-designed Isomorphic or peer drug enters or completes Phase 1 by end 2027 Codex Research Pack | Biotech/Longevity | 50% | |
| 0.60 | FDA ANDA211536: DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE (DAPAGLIFLOZIN) — CIPLA LTD | fda 2026-04-06 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.60 | FDA ANDA211479: DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE (DAPAGLIFLOZIN) — MSN | fda 2026-04-06 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.60 | FDA ANDA210480: LENALIDOMIDE (LENALIDOMIDE) — ALVOGEN | fda 2026-04-27 | CMQ_010 True AGI requires genuine scientific-discovery capabilities (AlphaFold-class breakthroughs) — brute-force LLM scaling alone is insufficient. Demis Hassabis | AI | 49% | |
| 0.60 | FDA BLA761467: KEYTRUDA QLEX (PEMBROLIZUMAB) — MERCK SHARP DOHME | fda 2026-06-24 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.60 | FDA NDA215430: AUVELITY (BUPROPION HYDROCHLORIDE) — AXSOME | fda 2026-04-30 | IND_010 Autonomous orbital manufacturing (facilitated by companies like Varda Space Industries) will successfully return pharmaceutical products processed in microgravity that are commercially superior to those manufactured on Earth by 2026 — new Biotech front... Jared Isaacman | Biotech/Longevity | 43% | |
| 0.60 | FDA ANDA216327: DILTIAZEM HYDROCHLORIDE (DILTIAZEM HYDROCHLORIDE) — SCIEGEN PHARMS | fda 2026-04-10 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.60 | FDA ANDA211582: DAPAGLIFLOZIN (DAPAGLIFLOZIN) — ZYDUS PHARMS | fda 2026-04-06 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.60 | FDA ANDA060469: TETRACYCLINE HYDROCHLORIDE (TETRACYCLINE HYDROCHLORIDE) — IMPAX LABS | fda 2026-04-17 | 245_009 Breaking plastic-degradation technology could become a supplement that breaks microplastics in the gut before absorption Peter Diamandis | Biotech/Longevity | 45% | |
| 0.60 | FDA ANDA201446: FALLBACK SOLO (LEVONORGESTREL) — LUPIN | fda 2026-05-01 | 233_019 Alpha plans to conduct a million-student pharmaceutical-grade randomized control trial on Timeback. Joe Liemandt | Education | 35% |